Respiratory Syncytial Virus (RSV) Diagnostic Market Look a Witness of Excellent Long-Term Growth – Worldwide Survey by 2

Comments · 6 Views

The Respiratory Syncytial Virus (RSV) Diagnostic Market is Segmented by Product (Kits and Reagents, Instruments, and Others), Method (Molecular Diagnostics, Rapid Antigen Detection Tests, Immunoassays, Flow Cytometry, Chromatography), End User (Hospitals and Clinics, Clinical Laboratories,

Respiratory Syncytial Virus (RSV) Diagnostic Market research report by Delvens focuses on primary sections such as – market segments, market outlook, competitive landscape, and company profiles. The segments provide details in terms of various perspectives such as end-use industry, product or service type, and any other relevant segmentation as per the market’s current scenario which includes various aspects to perform further marketing activity, the global Respiratory Syncytial Virus market size was estimated at USD 1.05 billion in 2023 and is projected to reach USD 2.2 billion in 2030 at a CAGR of 10.4% during the forecast period 2023-2030.

Get Free Sample Report: https://www.delvens.com/get-free-sample/respiratory-syncytial-virus-market

An increase in the number of clinical vaccination studies, an increase in the need for in-vitro diagnostics, an increase in the prevalence of pediatric pneumonia, and an increase in the usage of molecular diagnostics are other factors anticipated to propel the market.

The Prominent Players in The Respiratory Syncytial Virus Market are:

·        BIOMERIEUX

·        Abbott

·        F. Hoffman La. Roche Ltd

·        Danaher

·        Thermo Fisher Scientific Inc.

·        Luminex Corporation

·        BioCartis, Hologic, Inc.

·        Fast Track Diagnostics Luxembourg S.à r.l.

·        Beckman Coulter Inc.

·        Ortho-Clinical Diagnostics

·        Bio-Rad Laboratories Inc.

·        DiaSorin S.p.A.

·        Becton, Dickinson and Company

·        AbbVie, Inc.

·        AstraZeneca PLC

·        Atea Pharmaceuticals

·        Bausch Health Companies Inc.

·        Celltrion Inc.

·        Enanta Pharmaceuticals, Inc and More

The respiratory virus known as respiratory syncytial virus (RSV) attacks the lungs and bronchioles. The majority of children become unwell from it by the age of two, making it one of the prevalent causes of childhood disease. Adults can also contract RSV. Pneumonia and bronchitis are among the more serious RSV infections. One of the main drivers of market expansion is the rising sickness rate.

Modern technologies like bio- and nanotechnology are helping to develop current RSV detection procedures including the western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). In addition, government organizations from many nations provide funding for R&D initiatives to create novel treatments.

For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/respiratory-syncytial-virus-market

Recent Developments

In April 2022, Allplex RV Master Assay acquired the European CE-IVD certification and clearance from Australia's Therapeutic Goods Administration, according to a release from Seegene Inc. in April 2022. It can discriminate between two kinds of respiratory syncytial viruses and 21 targets for 19 distinct respiratory viruses.

In March 2022, SARS-CoV-2, influenza A and B, respiratory syncytial virus, and Pandemic Response Lab (PRL), a wholly-owned subsidiary of Opentrons Labworks Inc., introduced a condensed respiratory panel in March 2022. (RSV).

The Respiratory Syncytial Virus Market is segmented into various segments such as Product, Method, End User, Drug type, Dosage Form, Distribution channel, and region:

Based on Product

·        Kits and Assays

·        Instruments

·        Others

Based on the Method

·        Molecular Diagnostics

·        Rapid Antigen Detection Tests

·        Immunoassays

·        Flow Cytometry

·        Chromatography

·        Others

Based on the End User

·        Hospitals and Clinics

·        Clinical Laboratories

·        Others

Based on Drug type

·        Ribavirin

·        Synagis

·        Virazole

·        Palivizumab

·        Riba Tab

·        Others

Based on Dosage Form

·        Oral

·        Injectable

·        Inhaler

·        Other

Based on Distribution Channel

·        Hospital pharmacies

·        Drug Stores

·        Retail pharmacies

·        Clinics

Access Full Report: https://www.delvens.com/report/respiratory-syncytial-virus-market

In addition to the market data for the Respiratory Syncytial Virus Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.

More Reports Form Delvens:

Sternal Closure Systems market

Liposome Drug Delivery Market

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact us:

Unit No. 01, 3rd Floor, Plot No. 56, Block B

Sector 2 Noida, Near Noida Sector 15 Metro Station 201301, IN

+44 20 3290 6466

+0120- 4903958

sales@delvens.com

Comments